ライフサイエンスコーパス: malignant potential

1 alignant potential) or oncogenes (activating malignant potential).

2 heterogeneous group of lesions with diverse malignant potential.

3 or metastatic behavior and indicators of low malignant potential.

4 initiation occurs is a major determinant of malignant potential.

5 her the tumor has hormonal activity, and its malignant potential.

6 tal hyperplasia is a lesion with significant malignant potential.

7 l histological subtypes except tumors of low malignant potential.

8 and suggest that the difference may reflect malignant potential.

9 rade 2, 2 were of grade 1, and 3 were of low malignant potential.

10 d', with subclone mixing indicative of early malignant potential.

11 n before neoplasms have invaded and acquired malignant potential.

12 gical indicators of higher proliferative and malignant potential.

13 e development of lesions, some of which have malignant potential.

14 equently, thereby increasing tumorigenic and malignant potential.

15 sets of colorectal serrated polyps (SP) have malignant potential.

16 nt for invading cancers and to augment their malignant potential.

17 cytokines may identify those cysts with high malignant potential.

18 with no malignant potential from those with malignant potential.

19 sets of colorectal serrated polyps (SP) have malignant potential.

20 llary neoplasms (SPN), a rare tumor with low malignant potential.

21 hemotherapy and yielded tumors with enhanced malignant potential.

22 s rise to a population of cells with greater malignant potential.

23 certain types are associated with increased malignant potential.

24 all carcinoid tumors and all carcinoids have malignant potential.

25 cyte hyperplasia without invasiveness or pre-malignant potential.

26 endocrine tumors that occur in MEN 1 carry a malignant potential.

27 may be associated with pancreatitis or have malignant potential.

28 mpared with similar-sized adenomas that have malignant potential.

29 cystic neoplasms of the pancreas with clear malignant potential.

30 d neoplasms were benign or of a low grade of malignant potential.

31 ically heterogeneous neoplasms with variable malignant potential.

32 ll for its activity can greatly reduce their malignant potential.

33 -grade lymphoma in one patient indicates the malignant potential.

34 lial and stromal overgrowth but have limited malignant potential.

35 ast, are heterogeneous with respect to their malignant potential.

36 or metastatic behavior and indicators of low malignant potential.

37 with Stat3 activation being correlated with malignant potential.

38 d-stage ovarian cancer (III/IV)], 6 of 6 low malignant potential, 5 of the 6 benign tumors, and 9 of

39 By comparing cells with high and low malignant potential alongside their nontransformed count

40 this region, including 3 of 7 tumors of low malignant potential and 4 of 5 nonmetastatic carcinomas.

41 vels, are associated with both tumors of low malignant potential and carcinomas but not with cystaden

42 he reasons why HPPs with KRAS mutations lack malignant potential and compared the effects of Kras/KRA

43 disease (VHL) is challenging because of the malignant potential and difficulty in predicting prognos

44 24 patients, eight biomarker candidates for malignant potential and high-grade dysplasia/cancer were

45 rticle reviews 'classic' genodermatoses with malignant potential and highlights recent recommendation

46 ancers <3 cm in diameter behave with minimal malignant potential and likelihood of transmission to th

47 In patients, Shc expression correlated with malignant potential and overall survival.

48 umours has led to speculation that they lack malignant potential and represent a biological entity di

49 sm or mucinous cystic neoplasm) lesions have malignant potential and should be distinguished from ser

50 for accurate typing of the polyps to predict malignant potential and underlying possible genetic abno

51 rd that assumed that all polyps >/=10 mm had malignant potential and were considered neoplastic or hi

52 (benign), atypical Spitz tumor (intermediate malignant potential), and spitzoid melanoma (fully malig

53 eterogeneous neuroendocrine tumors that have malignant potential, and are most commonly found in the

54 atic mucinous cystic neoplasms (MCNs) harbor malignant potential, and current guidelines recommend re

55 erine cancer, uterine neoplasms of uncertain malignant potential, and endometrial hyperplasia were es

56 r histopathological presentation and limited malignant potential--and place Lkb1 in a distinct class

57 n approach is that indolent lesions with low malignant potential are common, and screening brings ind

58 Tumors of varying malignant potential arise from the complex epithelial li

59 vironment are enabled to fully express their malignant potential as evidenced by the alpha6beta4 inte

60 eatic cysts requires risk stratification for malignant potential based on the presence or absence of

61 ulation was observed in PDAC compared to low malignant potential BCT.

62 utaneous stigmata of the genodermatoses with malignant potential can lead to early diagnosis and init

63 Thus, histologically benign or low malignant potential components found in heterogeneous ov

64 ploidy in both histologically benign and low malignant potential components.

65 n each individual patient, in terms of their malignant potential, drug sensitivity, and their potenti

66 groups of ovarian tissues reflective of low malignant potential/early cancer onset and possible pre-

67 r pylori-related tumor of B-cell origin, the malignant potential for which remains to be defined in i

68 learly distinguishing cystic lesions with no malignant potential from those with malignant potential.

69 patients (including those with tumors of low malignant potential) had stage I disease, 5 had stage IV

70 mixing genetically marked keratinocytes with malignant potential (II-4) with normal keratinocytes at

71 CD44 expression is associated with enhanced malignant potential in esophageal squamous cell carcinom

72 tegrin and FAK significantly correlates with malignant potential in patients with triple-negative bre

73 lanomas using clinical factors predictive of malignant potential, in keeping with similar philosophy

74 changes in expression of putative markers of malignant potential, including p53, cyclin D1, and Ki-67

75 However, assessment of malignant potential is desirable for choice of treatment

76 which the identification of factors endowing malignant potential is strongly warranted.

77 thelial ovarian tumors [16 classified as low malignant potential (LMP) and 66 classified as primary o

78 aining benign ovarian tumors, borderline/low malignant potential (LMP) ovarian tumors as well as inva

79 Papillary serous low malignant potential (LMP) tumors are characterized by ma

80 ve epithelial ovarian carcinoma, 30 with low malignant potential (LMP) tumors, 16 with benign tumors,

81 ly stage) and 25 patients with tumors of low malignant potential (LMP).

82 mas (MAs) and ovarian mucinous tumors of low malignant potential (MLMPs) unassociated with PMP.

83 sive carcinomas compared with benign and low malignant potential neoplasms (P = 0.007), but no signif

84 g clonal selection in Barrett's and that the malignant potential of 'benign' Barrett's lesions is pre

85 Diminished malignant potential of Adp27KIP1-infected cells was mani

86 The malignant potential of cancer is dynamic, changing throu

87 e mechanisms by which c-erbB-2 increases the malignant potential of cells remains unclear.

88 enetic events associated with the origin and malignant potential of FTH are poorly understood.

89 We show that Mig-6 quells the malignant potential of GBM cells and dampens EGFR signal

90 s that can be used to predict accurately the malignant potential of histological prostate cancers.

91 ivin expression is associated with increased malignant potential of human gliomas.

92 hibition of IL-23p19 was shown to reduce the malignant potential of lesions established by MCA inocul

93 shown previously to correlate with enhanced malignant potential of many human tumor types, including

94 Although the malignant potential of PIN IV in mice has not been prove

95 d also provides a critical constraint to the malignant potential of Rb mutant tumor cells.

96 s been studied as a tool to help predict the malignant potential of sarcomas, prognosis of patients a

97 egree of angiogenesis is correlated with the malignant potential of several cancers, including breast

98 The malignant potential of smooth muscle tumors correlates s

99 Nevertheless, the malignant potential of SSIM cells remains undetermined.

100 ose of typical surface Barrett's glands, the malignant potential of the buried glands, especially whe

101 The molecular basis for the malignant potential of the HGF/SF-Met signal in cancer c

102 Here, we have investigated the malignant potential of the high-grade PIN lesions that f

103 whereas native NRG stimulation increased the malignant potential of the same cells.

104 spectrum between normal differentiation and malignant potential of these cells reflects the dynamic

105 Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfun

106 s and abnormal gene expression, increase the malignant potential of tumors by affecting pathways that

107 thodologies for using nucleoli to assess the malignant potential of uveal melanoma.

108 To investigate the malignant potential of viable circulating carcinoma cell

109 As can work as tumor suppressors (inhibiting malignant potential) or oncogenes (activating malignant

110 hologic finding (cancer, tumors of uncertain malignant potential, or endometrial hyperplasia) were 0.

111 le of chromosomal instability in determining malignant potential over a broad range of tumors.

112 Melanoma cells with high malignant potential (PDGFR-positive, c-Kit-negative) or

113 tial (PDGFR-positive, c-Kit-negative) or low malignant potential (PDGFR-positive, c-Kit-positive) wer

114 Its malignant potential places careproviders in a clinical d

115 rian tumors (BOTs), or ovarian tumors of low malignant potential, represent a distinct category of ep

116 levels of EP4 influence important markers of malignant potential, such as anchorage-independent growt

117 PTs) are unusual pancreatic neoplasms of low malignant potential that most frequently affect young wo

118 like cell population in NSCLC with increased malignant potential, the elucidation of which may enable

119 used ovarian epithelial tumors of different malignant potential to look for associations between 5'-

120 ies the gene regulatory network that confers malignant potential to neural tumors with early developm

121 on of this gene in 44 ovarian tumors (12 low malignant potential tumors and 32 carcinomas) and 10 nor

122 n were significantly elevated in 7 of 12 low malignant potential tumors and in 27 of 32 carcinomas.

123 ificantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79-0.91;

124 udies suggest that ovarian cystadenomas, low malignant potential tumors, and carcinomas are not part

125 lts The optimal set of markers for detecting malignant potential was a panel of peptides from mucin-5

126 (cSCC), the most frequent skin neoplasm with malignant potential, we have developed an integrated app

127 )-positive cells, suggesting that cells with malignant potential were eliminated from the tissue at t

128 ive in the detection of lesions that have no malignant potential when compared with similar-sized ade

129 ich exhibits low expression of GRO-alpha and malignant potential with a pActin-KC vector encoding mGR

130 c benign cystic tumors (BCT) of low and high malignant potential with PDAC, in order to identify miRN